{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:55:04Z","timestamp":1791903304005,"version":"4.3.4"},"reference-count":44,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,13]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Exposure to chemotherapy (CT) and\/or radiotherapy increases the risk of therapy-related myeloid neoplasms (t-MN), a heterogeneous group of disorders currently classified by treatment history rather than molecular features. Although germ line predisposition has been suggested in \u223c20% of patients, its prevalence and clinical impact remain insufficiently defined. To address this, we analyzed 100 patients with t-MN by integrating clinical characteristics, prior treatment regimens, and genomic profiling. Somatic and germ line variants were identified using targeted next-generation sequencing (n = 33) or whole-exome sequencing (n = 67). Somatic abnormalities, including cytogenetic and\/or molecular alterations, were detected in 89.8% of patients. Germ line variants were identified in 32.3% of patients, including mutations in cancer predisposition genes (19.8%) and myeloid disease\u2013related genes (14.6%). Patient stratification by germ line landscape and gene category defined 2 prognostic scenarios and 3 subgroups with distinct clinical outcomes. Patients harboring germ line cancer predisposition variants were enriched for TP53 mutations and complex karyotypes and had an adverse prognosis. In contrast, patients with germ line myeloid-related variants and those without detectable germ line variants exhibited recurrent mutations in TET2, DNMT3A, SF3B1, SRSF2, RUNX1, and ASXL1, were associated with normal karyotypes, and had favorable outcomes. These findings underscore the importance of the germ line landscape in t-MN pathogenesis and support its incorporation into disease classification and risk stratification. Notably, CT exposure was associated with complex karyotypes and poor prognosis in patients with germ line cancer predisposition variants, highlighting a subgroup that may benefit from targeted surveillance and preventive strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020704","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T23:30:47Z","timestamp":1783726247000},"page":"6703-6718","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Germ line landscape stratification defines distinct molecular and prognostic groups in therapy-related myeloid neoplasms"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2623-2876","authenticated-orcid":false,"given":"Oriol","family":"Calvete","sequence":"first","affiliation":[{"name":"1Myelodysplastic Syndromes Research Group, Josep Carreras Leukaemia Research Institute, Catalan Institute of Oncology-Hospital Germans Trias i Pujol, Universitat Aut\u00f2noma de Barcelona, Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4809-3897","authenticated-orcid":false,"given":"Julia","family":"Mestre","sequence":"additional","affiliation":[{"name":"1Myelodysplastic Syndromes Research Group, Josep Carreras Leukaemia Research Institute, Catalan Institute of Oncology-Hospital Germans Trias i Pujol, Universitat Aut\u00f2noma de Barcelona, Badalona, Spain"},{"name":"2Facultat de Bioci\u00e8ncies, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6806-9342","authenticated-orcid":false,"given":"Lorea","family":"Chaparro-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"1Myelodysplastic Syndromes Research Group, Josep Carreras Leukaemia Research Institute, Catalan Institute of Oncology-Hospital Germans Trias i Pujol, Universitat Aut\u00f2noma de Barcelona, Badalona, Spain"},{"name":"2Facultat de Bioci\u00e8ncies, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7246-2433","authenticated-orcid":false,"given":"Luc\u00eda Ruiz","family":"P\u00e9rez-Hita","sequence":"additional","affiliation":[{"name":"1Myelodysplastic Syndromes Research Group, Josep Carreras Leukaemia Research Institute, Catalan Institute of Oncology-Hospital Germans Trias i Pujol, Universitat Aut\u00f2noma de Barcelona, Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8377-7573","authenticated-orcid":false,"given":"Alba","family":"Mesa","sequence":"additional","affiliation":[{"name":"3Haematology Department, Catalan Institute of Oncology-Hospital Germans Trias i Pujol, Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0295-1307","authenticated-orcid":false,"given":"Blanca","family":"Xicoy","sequence":"additional","affiliation":[{"name":"3Haematology Department, Catalan Institute of Oncology-Hospital Germans Trias i Pujol, Badalona, Spain"},{"name":"4Myeloid Neoplasm Group, Josep Carreras Leukaemia Research Institute, Catalan Institute of Oncology-Hospital Germans Trias i Pujol, Universitat Aut\u00f2noma de Barcelona, Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1713-7110","authenticated-orcid":false,"given":"Lurdes","family":"Zamora","sequence":"additional","affiliation":[{"name":"3Haematology Department, Catalan Institute of Oncology-Hospital Germans Trias i Pujol, Badalona, Spain"},{"name":"4Myeloid Neoplasm Group, Josep Carreras Leukaemia Research Institute, Catalan Institute of Oncology-Hospital Germans Trias i Pujol, Universitat Aut\u00f2noma de Barcelona, Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4275-0104","authenticated-orcid":false,"given":"Isabel","family":"Granada","sequence":"additional","affiliation":[{"name":"3Haematology Department, Catalan Institute of Oncology-Hospital Germans Trias i Pujol, Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7741-498X","authenticated-orcid":false,"given":"Mar","family":"Mallo","sequence":"additional","affiliation":[{"name":"1Myelodysplastic Syndromes Research Group, Josep Carreras Leukaemia Research Institute, Catalan Institute of Oncology-Hospital Germans Trias i Pujol, Universitat Aut\u00f2noma de Barcelona, Badalona, Spain"},{"name":"5Microarrays Unit, Josep Carreras Leukaemia Research Institute, Catalan Institute of Oncology-Hospital Germans Trias i Pujol, Universitat Aut\u00f2noma de Barcelona, Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5025-352X","authenticated-orcid":false,"given":"Emili","family":"Cid","sequence":"additional","affiliation":[{"name":"1Myelodysplastic Syndromes Research Group, Josep Carreras Leukaemia Research Institute, Catalan Institute of Oncology-Hospital Germans Trias i Pujol, Universitat Aut\u00f2noma de Barcelona, Badalona, Spain"},{"name":"6Laboratory of Immunohematology and Glycobiology, Josep Carreras Leukaemia Research Institute, Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7308-1273","authenticated-orcid":false,"given":"Estefania","family":"Mancini","sequence":"additional","affiliation":[{"name":"1Myelodysplastic Syndromes Research Group, Josep Carreras Leukaemia Research Institute, Catalan Institute of Oncology-Hospital Germans Trias i Pujol, Universitat Aut\u00f2noma de Barcelona, Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0904-4682","authenticated-orcid":false,"given":"Claudia","family":"Lozano","sequence":"additional","affiliation":[{"name":"1Myelodysplastic Syndromes Research Group, Josep Carreras Leukaemia Research Institute, Catalan Institute of Oncology-Hospital Germans Trias i Pujol, Universitat Aut\u00f2noma de Barcelona, Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3176-6271","authenticated-orcid":false,"given":"Laura","family":"Palomo","sequence":"additional","affiliation":[{"name":"3Haematology Department, Catalan Institute of Oncology-Hospital Germans Trias i Pujol, Badalona, Spain"},{"name":"4Myeloid Neoplasm Group, Josep Carreras Leukaemia Research Institute, Catalan Institute of Oncology-Hospital Germans Trias i Pujol, Universitat Aut\u00f2noma de Barcelona, Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4528-1219","authenticated-orcid":false,"given":"Pamela","family":"Acha","sequence":"additional","affiliation":[{"name":"7Experimental Hematology, Hematology Department, Vall d\u2019Hebr\u00f3n Institute of Oncology, Hospital Universitari Vall d\u2019Hebr\u00f3n, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9532-7417","authenticated-orcid":false,"given":"Mar\u00eda Julia","family":"Montoro","sequence":"additional","affiliation":[{"name":"7Experimental Hematology, Hematology Department, Vall d\u2019Hebr\u00f3n Institute of Oncology, Hospital Universitari Vall d\u2019Hebr\u00f3n, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9140-0610","authenticated-orcid":false,"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[{"name":"8Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney","family":"DiNardo","sequence":"additional","affiliation":[{"name":"8Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-2482","authenticated-orcid":false,"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[{"name":"8Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Montalban-Bravo","sequence":"additional","affiliation":[{"name":"8Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3902-474X","authenticated-orcid":false,"given":"Neus","family":"Torres-Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"9Hematology Research Group, Instituto de Investigaci\u00f3n Sanitaria La Fe, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Santiago-Balsera","sequence":"additional","affiliation":[{"name":"10Haematology Service and Genetics Unit, Hospital Universitario y Polit\u00e9cnico La Fe, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8252-1106","authenticated-orcid":false,"given":"Jos\u00e9","family":"Cervera","sequence":"additional","affiliation":[{"name":"10Haematology Service and Genetics Unit, Hospital Universitario y Polit\u00e9cnico La Fe, Valencia, Spain"},{"name":"11Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7574-9462","authenticated-orcid":false,"given":"Gonzalo","family":"Maortua","sequence":"additional","affiliation":[{"name":"12Hospital Universitario la Paz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1627-0817","authenticated-orcid":false,"given":"Raquel","family":"de Paz","sequence":"additional","affiliation":[{"name":"12Hospital Universitario la Paz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00ed","family":"Mascar\u00f3","sequence":"additional","affiliation":[{"name":"13Hospital Son Llatzer, Palma, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4470-4652","authenticated-orcid":false,"given":"Alfonso","family":"Garc\u00eda Da Vila","sequence":"additional","affiliation":[{"name":"13Hospital Son Llatzer, Palma, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9293-2029","authenticated-orcid":false,"given":"Sara","family":"Garc\u00eda-\u00c1vila","sequence":"additional","affiliation":[{"name":"14Hematology Department, Hospital del Mar, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4741-7925","authenticated-orcid":false,"given":"Juan Jos\u00e9","family":"Rodriguez-Sevilla","sequence":"additional","affiliation":[{"name":"15Department of Hematology, Hospital Clinic, Barcelona, Spain"},{"name":"16Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8176-7179","authenticated-orcid":false,"given":"Leonor","family":"Arenillas","sequence":"additional","affiliation":[{"name":"15Department of Hematology, Hospital Clinic, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Bellosillo","sequence":"additional","affiliation":[{"name":"17Pathology Service, Hospital del Mar, Hospital del Mar Research Institute, Universitat Pompeu Fabra, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7829-5249","authenticated-orcid":false,"given":"Rashmi","family":"Kanagal-Shamanna","sequence":"additional","affiliation":[{"name":"8Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3251-2161","authenticated-orcid":false,"given":"Francesc","family":"Sol\u00e9","sequence":"additional","affiliation":[{"name":"1Myelodysplastic Syndromes Research Group, Josep Carreras Leukaemia Research Institute, Catalan Institute of Oncology-Hospital Germans Trias i Pujol, Universitat Aut\u00f2noma de Barcelona, Badalona, Spain"},{"name":"2Facultat de Bioci\u00e8ncies, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"issue":"7","key":"2026101310412834400_bib1","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular International Prognostic Scoring System for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"issue":"7","key":"2026101310412834400_bib2","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2026101310412834400_bib3","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2026101310412834400_bib4","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3324\/haematol.2022.281233","article-title":"Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications","volume":"108","author":"Nilsson","year":"2022","journal-title":"Haematologica"},{"issue":"5","key":"2026101310412834400_bib5","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.3390\/biomedicines12051054","article-title":"Therapy-related myeloid neoplasm: biology and mechanistic aspects of malignant progression","volume":"12","author":"Travaglini","year":"2024","journal-title":"Biomedicines"},{"issue":"10","key":"2026101310412834400_bib6","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.1007\/s00277-025-06651-0","article-title":"Post-cytotoxic myeloid neoplasms: a comprehensive analysis of clinicopathologic, genetic profile, latency determinants, and potential prognostic predictors- a single centre study","volume":"104","author":"Soliman","year":"2025","journal-title":"Ann Hematol"},{"issue":"2","key":"2026101310412834400_bib7","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","article-title":"Unanswered questions following reports of secondary malignancies after CAR-T cell therapy","volume":"30","author":"Levine","year":"2024","journal-title":"Nat Med"},{"issue":"9","key":"2026101310412834400_bib8","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: when genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"31","key":"2026101310412834400_bib9","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","article-title":"Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study","volume":"33","author":"Granfeldt \u00d8stg\u00e5rd","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026101310412834400_bib10","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2643-3230.BCD-24-0103","article-title":"Therapy-related myeloid neoplasms: complex interactions among cytotoxic therapies, genetic factors, and aberrant microenvironment","volume":"5","author":"Singhal","year":"2024","journal-title":"Blood Cancer Discov"},{"issue":"3","key":"2026101310412834400_bib11","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41375-020-0917-7","article-title":"Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification\u2014an approach to classification of patients with t-MDS","volume":"35","author":"Kuendgen","year":"2021","journal-title":"Leukemia"},{"issue":"12","key":"2026101310412834400_bib12","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1038\/s41375-019-0479-8","article-title":"The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution","volume":"33","author":"Singhal","year":"2019","journal-title":"Leukemia"},{"issue":"9","key":"2026101310412834400_bib13","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1182\/blood.2022018236","article-title":"TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype","volume":"141","author":"Hiwase","year":"2023","journal-title":"Blood"},{"issue":"15","key":"2026101310412834400_bib14","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2026101310412834400_bib15","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.bulcan.2023.02.022","article-title":"Therapy-related myelodysplastic syndromes in the genomics era","volume":"110","author":"Renneville","year":"2023","journal-title":"Bull Cancer"},{"issue":"5","key":"2026101310412834400_bib16","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.stem.2018.10.004","article-title":"PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy","volume":"23","author":"Hsu","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"3","key":"2026101310412834400_bib17","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.3324\/haematol.2019.219352","article-title":"Genomics of therapy-related myeloid neoplasms","volume":"105","author":"Kuzmanovic","year":"2020","journal-title":"Haematologica"},{"issue":"5","key":"2026101310412834400_bib18","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/ijc.23212","article-title":"Family history of breast or ovarian cancer modifies the risk of secondary leukemia after breast cancer: results from a population-based study","volume":"122","author":"Verkooijen","year":"2008","journal-title":"Int J Cancer"},{"issue":"16","key":"2026101310412834400_bib19","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood.2021014956","article-title":"Lenalidomide promotes the development of TP53 -mutated therapy-related myeloid neoplasms","volume":"140","author":"Sperling","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2026101310412834400_bib20","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.3390\/cancers15051483","article-title":"The secondary myelodysplastic neoplasms (MDS) jigsaw","volume":"15","author":"Calvete","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2026101310412834400_bib21","doi-asserted-by":"crossref","first-page":"11640","DOI":"10.1038\/s41598-021-91142-1","article-title":"Confirming putative variants at \u2264 5% allele frequency using allele enrichment and Sanger sequencing","volume":"11","author":"Yan","year":"2021","journal-title":"Sci Rep"},{"issue":"3","key":"2026101310412834400_bib22","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1001\/jamaoncol.2018.5625","article-title":"Association of chemotherapy for solid tumors with development of therapy-related myelodysplastic syndrome or acute myeloid leukemia in the modern era","volume":"5","author":"Morton","year":"2019","journal-title":"JAMA Oncol"},{"issue":"12","key":"2026101310412834400_bib23","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised International Prognostic Scoring System for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2026101310412834400_bib24","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","article-title":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","volume":"52","author":"Bolton","year":"2020","journal-title":"Nat Genet"},{"key":"2026101310412834400_bib25","first-page":"CD007110","article-title":"Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma","volume":"2","author":"Rehan","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2026101310412834400_bib26","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/IGC.0000000000000856","article-title":"Comparison of survival benefits of combined chemotherapy and radiotherapy versus chemotherapy alone for uterine serous carcinoma","volume":"27","author":"Lin","year":"2017","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"2026101310412834400_bib27","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12876-021-01742-4","article-title":"Chemotherapy alone versus definitive concurrent chemoradiotherapy for cT4b esophageal squamous cell carcinoma: a population-based study","volume":"21","author":"Li","year":"2021","journal-title":"BMC Gastroenterol"},{"issue":"5","key":"2026101310412834400_bib28","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1200\/JCO.2012.44.5791","article-title":"Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials","volume":"31","author":"Koontz","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7540","key":"2026101310412834400_bib29","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"},{"issue":"6","key":"2026101310412834400_bib30","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N Engl J Med Overseas Ed"},{"issue":"10","key":"2026101310412834400_bib31","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat Med"},{"issue":"9","key":"2026101310412834400_bib32","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/bloodadvances.2021006239","article-title":"TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS\/AML","volume":"6","author":"Weinberg","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2026101310412834400_bib33","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(16)30626-X","article-title":"Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study","volume":"18","author":"Takahashi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"2026101310412834400_bib34","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/cncr.29615","article-title":"Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia","volume":"122","author":"Churpek","year":"2016","journal-title":"Cancer"},{"issue":"3","key":"2026101310412834400_bib35","doi-asserted-by":"crossref","first-page":"101197","DOI":"10.1016\/j.beha.2020.101197","article-title":"Germline predisposition in myeloid neoplasms: unique genetic and clinical features of GATA2 deficiency and SAMD9\/SAMD9L syndromes","volume":"33","author":"Sahoo","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"issue":"22","key":"2026101310412834400_bib36","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2015-04-641100","article-title":"Genomic analysis of germ line and somatic variants in familial myelodysplasia\/acute myeloid leukemia","volume":"126","author":"Churpek","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2026101310412834400_bib37","first-page":"46","article-title":"Molecular pathogenesis in myeloid neoplasms with germline predisposition","volume":"12","author":"Gao","year":"2021","journal-title":""},{"issue":"7","key":"2026101310412834400_bib38","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/s41375-018-0051-y","article-title":"Universal genetic testing for inherited susceptibility in children and adults with myelodysplastic syndrome and acute myeloid leukemia: are we there yet?","volume":"32","author":"Tawana","year":"2018","journal-title":"Leukemia"},{"issue":"R2","key":"2026101310412834400_bib39","doi-asserted-by":"crossref","first-page":"R225","DOI":"10.1093\/hmg\/ddab141","article-title":"Germline predisposition to hematopoietic malignancies","volume":"30","author":"Feurstein","year":"2021","journal-title":"Hum Mol Genet"},{"issue":"5","key":"2026101310412834400_bib40","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/jha2.1012","article-title":"Beyond myeloid neoplasms germline guidelines: validation of the thresholds criteria in the search of germline predisposition variants","volume":"5","author":"Mestre","year":"2024","journal-title":"EJHaem"},{"key":"2026101310412834400_bib41","first-page":"1","article-title":"BCHE as a prognostic biomarker in endometrial cancer and its correlation with immunity","volume":"2022","author":"Liu","year":"2022","journal-title":"J Immunol Res"},{"issue":"1","key":"2026101310412834400_bib42","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12920-025-02213-5","article-title":"Mono-allelic MUTYH mutation as the likely inherited etiology of hereditary breast cancer in a patient from a multi-cancer family- report of a family and literature review","volume":"18","author":"Sarmadi","year":"2025","journal-title":"BMC Med Genomics"},{"issue":"1","key":"2026101310412834400_bib43","first-page":"e1735","article-title":"Regulator of telomere elongation helicase 1 gene and its association with malignancy","volume":"6","author":"Hassani","year":"2023","journal-title":"Cancer Rep"},{"issue":"7","key":"2026101310412834400_bib44","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.gim.2022.03.008","article-title":"Age of first cancer diagnosis and survival in Bloom syndrome","volume":"24","author":"Sugra\u00f1es","year":"2022","journal-title":"Genet Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6703\/2592951\/blooda_adv-2026-020704-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6703\/2592951\/blooda_adv-2026-020704-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:41:39Z","timestamp":1791902499000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/19\/6703\/569671\/Germ-line-landscape-stratification-defines"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":44,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,10,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020704","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,13]]},"published":{"date-parts":[[2026,9,30]]}}}